Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 61 clinical trials
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells that are lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor cavity or …

posterior fossa tumors
tumor resection
cancer chemotherapy
viral therapy
supratentorial tumors
  • 7 views
  • 25 Mar, 2022
  • 1 location
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed …

  • 4 views
  • 04 Oct, 2022
  • 9 locations
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or ventricular system …

tumor resection
cancer chemotherapy
supratentorial tumors
cns neoplasm
dipg
  • 8 views
  • 09 May, 2022
  • 1 location
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, …

anaplastic astrocytoma
cancer chemotherapy
astrocytoma
malignant cerebellar tumor
monoclonal antibody therapy
  • 84 views
  • 04 Oct, 2022
  • 1 location
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral blood stem cell transplant. For solid tumors, if appropriate, …

progressive disease
testicular
primary tumor
tumor markers
stem cell transplantation
  • 209 views
  • 04 May, 2022
  • 1 location
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this phase 1 trial is to determine the maximum tolerated dose (MTD), food effect, safety and tolerability of oral ONC206 in patients with recurrent, primary CNS neoplasms.

anaplastic astrocytoma
cancer chemotherapy
astrocytoma
measurable disease
cns tumor
  • 10 views
  • 12 Mar, 2022
  • 1 location
A Phase 1 Study of Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)

intrinsic pontine glioma (DIPG), high-grade glioma (adult and pediatric), medulloblastoma, and embryonal tumors formerly called Primitive Neuro-Ectodermal Tumors (PNET). Safety studies in humans have proven

  • 0 views
  • 28 Oct, 2022
  • 1 location
Memory Neuroimaging in Children, Adolescents and Young Adults Following Pediatric Cancer (IMPALA)

irradiation of the posterior fossa) or completely irradiated (e.g. included in the prophylactic irradiation of medulloblastoma prior to dose supplementation in the posterior fossa). On the other hand, the

medulloblastoma
brain tumor
Accepts healthy volunteers
  • 0 views
  • 02 Mar, 2022
  • 1 location
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes …

bone marrow infiltration
measurable disease
interleukins
radiopharmaceutical
stem cell infusion
  • 395 views
  • 23 Oct, 2022
  • 94 locations
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B)

This study is for patients with high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) or medulloblastoma or another rare brain cancer that expresses GD2. Because there is no

gene transfer
malignant glioma
cancer chemotherapy
cyclophosphamide
measurable disease
  • 1 views
  • 18 Oct, 2022
  • 1 location